Comparing the effectiveness and cost-effectiveness of sulfonylureas and newer diabetes drugs as second-line therapy for patients with type 2 diabetes.

Matteo FranchiGiacomo PellegriniAngelo AvogaroGiuliano BuzzettiRiccardo CandidoArturo CavaliereAgostino ConsoliIrene MarzonaFrancesco Saverio MenniniStefano PalcicGiovanni Corrao

Published in: BMJ open diabetes research & care (2024)

Newer diabetes drugs are more effective and cost-effective second-line options for the treatment of type 2 diabetes than SUs.

Keyphrases

type diabetes
cardiovascular disease
glycemic control
randomized controlled trial
metabolic syndrome
adipose tissue
weight loss